Legislation for Capping Prescription Drug Prices in State-Level Insurance Programs

A proposed legislative model aims to use Medicare-negotiated maximum fair prices (MFP) to cap reimbursement for prescription drugs at the state level. The framework seeks to validate cost savings and incorporate public feedback, potentially reshaping how drug pricing impacts state-funded insurance programs.

Legislative Intent

This initiative targets the financial strain of high prescription drug costs on public health and economic well-being. High medication prices often obstruct access to essential healthcare services, inflating overall health care expenditures, especially for state-sponsored insurance plans.

Definitions and Implementation

The legislation defines "State Entity" as any state agency purchasing drugs, excluding Medicaid programs. It also introduces the "Upper Payment Limit" as the cap for MFP-designated drugs. An authority, yet to be appointed, will oversee these regulatory compliance requirements.

Drug Evaluation and Savings Validation

The designated authority will conduct annual assessments of drugs meeting MFP criteria and estimate savings from implementing these limits. This process involves collaboration with Medicaid, health plan administrators, and potentially third-party data analysts. Payers and PBMs must disclose pricing and spending data to support these evaluations.

Public Commentary and Price Setting

Following savings calculations, the authority will solicit public comments, particularly from manufacturers. If significant savings are identified, they will set an upper payment limit not below the MFP, providing justification for higher caps if necessary.

ERISA Plan Participation and Rulemaking

ERISA plans may choose to apply the upper payment limits. The authority is authorized to devise detailed regulations under state administrative procedures to effectively implement these rules and ensure compliance.

Reporting Savings and Enforcement

Entities benefiting from cost savings must use them to lower healthcare expenses and report annually on financial impacts. Non-compliance could result in fines, with the Attorney General enforcing penalties to maintain regulatory standards.

Drug Withdrawal Prohibition

Manufacturers are prohibited from withdrawing drugs to evade price caps, with penalties for unauthorized withdrawals. A 180-day notice is required for any planned withdrawal, reinforcing regulatory adherence and risk management in drug supply continuity.

Severability

The legislation incorporates a severability clause, ensuring that any invalid provisions do not undermine the enforceability of the overall legal framework, maintaining the model's integrity and compliance objectives.